21-Aug-2014, Solicited, Patient/Consumer Serious report ((b) (6) ).
A patient reported the case. The patient was part of (b) (6)
About the program : (b) (6)
(b) (6)
A  case of a 40-Years-old Female patient who received COPAXONE (GLATIRAMER ACETATE, Product is or 
cannot be excluded as a Teva product). 
The patient took COPAXONE for MULTIPLE SCLEROSIS (GLATIRAMER ACETATE, Injection, Unknown, from 
05-Feb-2012).
While on the suspect medication, the patient experienced JC VIRUS(Serious , since 21-Aug-2014) . 
At the time of the report the outcome of the AEs were:   JC VIRUS : Unknown.
Action taken with suspect drugs: COPAXONE - Dosage maintained.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 255 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The patient had medical history of MULTIPLE SCLEROSIS(Continuing).
The patient's concomitant medication were unspecified.
The patient's past medication were unspecified.
Lab tests were not reported.
This case was considered serious based on the following criteria: (Other Serious (Important Medical Events))
Summary/Follow Up=JC Virus
Other Potentially Serious Event=Pt diagnosed with JC Virus. Exact date unknown.
Other Event Date=8/21/14
Teva Comment:  GLATIRAMER ACETATE: No information was provided on the reason for JC virus testing, as well
as the patient's concomitant medications, medical history, and any previous medications the patient received that 
may be associated with JC virus. Additional information is needed for an adequate assessment. Causality: Not 
Assessable
29-Aug-2014:
Duplicate cases identified. This case will be retained and case 504855USA will be deleted. All subsequent follow-up
information will be reported in this case. 
Information reported in case 504855USA that was not reported in 504511USA:
Do not call or mail the patient. 
Teva Comment: No medical comment.